224 related articles for article (PubMed ID: 26921342)
1. Delivery of Therapeutics Targeting the mRNA-Binding Protein HuR Using 3DNA Nanocarriers Suppresses Ovarian Tumor Growth.
Huang YH; Peng W; Furuuchi N; Gerhart J; Rhodes K; Mukherjee N; Jimbo M; Gonye GE; Brody JR; Getts RC; Sawicki JA
Cancer Res; 2016 Mar; 76(6):1549-59. PubMed ID: 26921342
[TBL] [Abstract][Full Text] [Related]
2. Targeting the mRNA-binding protein HuR impairs malignant characteristics of pancreatic ductal adenocarcinoma cells.
Jimbo M; Blanco FF; Huang YH; Telonis AG; Screnci BA; Cosma GL; Alexeev V; Gonye GE; Yeo CJ; Sawicki JA; Winter JM; Brody JR
Oncotarget; 2015 Sep; 6(29):27312-31. PubMed ID: 26314962
[TBL] [Abstract][Full Text] [Related]
3. Folate receptor-targeted nanoparticle delivery of HuR-RNAi suppresses lung cancer cell proliferation and migration.
Muralidharan R; Babu A; Amreddy N; Basalingappa K; Mehta M; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
J Nanobiotechnology; 2016 Jun; 14(1):47. PubMed ID: 27328938
[TBL] [Abstract][Full Text] [Related]
4. Modulation of the mRNA-binding protein HuR as a novel reversal mechanism of epirubicin-triggered multidrug resistance in colorectal cancer cells.
Lin GL; Ting HJ; Tseng TC; Juang V; Lo YL
PLoS One; 2017; 12(10):e0185625. PubMed ID: 28968471
[TBL] [Abstract][Full Text] [Related]
5. Posttranscriptional Regulation of the Inflammatory Marker C-Reactive Protein by the RNA-Binding Protein HuR and MicroRNA 637.
Kim Y; Noren Hooten N; Dluzen DF; Martindale JL; Gorospe M; Evans MK
Mol Cell Biol; 2015 Dec; 35(24):4212-21. PubMed ID: 26438598
[TBL] [Abstract][Full Text] [Related]
6. Transcriptomic-Wide Discovery of Direct and Indirect HuR RNA Targets in Activated CD4+ T Cells.
Techasintana P; Davis JW; Gubin MM; Magee JD; Atasoy U
PLoS One; 2015; 10(7):e0129321. PubMed ID: 26162078
[TBL] [Abstract][Full Text] [Related]
7. Polymer-based delivery of RNA-based therapeutics in ovarian cancer.
Weirauch U; Gutsch D; Höbel S; Aigner A
Methods Mol Biol; 2013; 1049():443-65. PubMed ID: 23913237
[TBL] [Abstract][Full Text] [Related]
8. Efficient siRNA delivery and tumor accumulation mediated by ionically cross-linked folic acid-poly(ethylene glycol)-chitosan oligosaccharide lactate nanoparticles: for the potential targeted ovarian cancer gene therapy.
Li TS; Yawata T; Honke K
Eur J Pharm Sci; 2014 Feb; 52():48-61. PubMed ID: 24178005
[TBL] [Abstract][Full Text] [Related]
9. HuR Promotes Ovarian Cancer Cell Proliferation by Regulating TIMM44 mRNA Stability.
Yu X; Li Y; Ding Y; Zhang H; Ding N; Lu M
Cell Biochem Biophys; 2020 Dec; 78(4):447-453. PubMed ID: 32901414
[TBL] [Abstract][Full Text] [Related]
10. Tumor-targeted Nanoparticle Delivery of HuR siRNA Inhibits Lung Tumor Growth
Muralidharan R; Babu A; Amreddy N; Srivastava A; Chen A; Zhao YD; Kompella UB; Munshi A; Ramesh R
Mol Cancer Ther; 2017 Aug; 16(8):1470-1486. PubMed ID: 28572169
[TBL] [Abstract][Full Text] [Related]
11. HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival.
Davidson B; Holth A; Hellesylt E; Hadar R; Katz B; Tropé CG; Reich R
Hum Pathol; 2016 Feb; 48():95-101. PubMed ID: 26640230
[TBL] [Abstract][Full Text] [Related]
12. Silencing the double-stranded RNA binding protein DGCR8 inhibits ovarian cancer cell proliferation, migration, and invasion.
Guo Y; Tian P; Yang C; Liang Z; Li M; Sims M; Lu L; Zhang Z; Li H; Pfeffer LM; Yue J
Pharm Res; 2015 Mar; 32(3):769-78. PubMed ID: 25823356
[TBL] [Abstract][Full Text] [Related]
13. Identification and validation of novel small molecule disruptors of HuR-mRNA interaction.
Wu X; Lan L; Wilson DM; Marquez RT; Tsao WC; Gao P; Roy A; Turner BA; McDonald P; Tunge JA; Rogers SA; Dixon DA; Aubé J; Xu L
ACS Chem Biol; 2015 Jun; 10(6):1476-84. PubMed ID: 25750985
[TBL] [Abstract][Full Text] [Related]
14. LncRNA OIP5-AS1/cyrano sponges RNA-binding protein HuR.
Kim J; Abdelmohsen K; Yang X; De S; Grammatikakis I; Noh JH; Gorospe M
Nucleic Acids Res; 2016 Mar; 44(5):2378-92. PubMed ID: 26819413
[TBL] [Abstract][Full Text] [Related]
15. Cytoplasmic overexpression of RNA-binding protein HuR is a marker of poor prognosis in meningioma, and HuR knockdown decreases meningioma cell growth and resistance to hypoxia.
Gauchotte G; Hergalant S; Vigouroux C; Casse JM; Houlgatte R; Kaoma T; Helle D; Brochin L; Rech F; Peyre M; Labrousse F; Vallar L; Guéant JL; Vignaud JM; Battaglia-Hsu SF
J Pathol; 2017 Aug; 242(4):421-434. PubMed ID: 28493484
[TBL] [Abstract][Full Text] [Related]
16. PKM2 uses control of HuR localization to regulate p27 and cell cycle progression in human glioblastoma cells.
Mukherjee J; Ohba S; See WL; Phillips JJ; Molinaro AM; Pieper RO
Int J Cancer; 2016 Jul; 139(1):99-111. PubMed ID: 26874904
[TBL] [Abstract][Full Text] [Related]
17. Cytoplasmic HuR expression correlates with poor outcome and with cyclooxygenase 2 expression in serous ovarian carcinoma.
Erkinheimo TL; Lassus H; Sivula A; Sengupta S; Furneaux H; Hla T; Haglund C; Butzow R; Ristimäki A
Cancer Res; 2003 Nov; 63(22):7591-4. PubMed ID: 14633672
[TBL] [Abstract][Full Text] [Related]
18. HuR silencing elicits oxidative stress and DNA damage and sensitizes human triple-negative breast cancer cells to radiotherapy.
Mehta M; Basalingappa K; Griffith JN; Andrade D; Babu A; Amreddy N; Muralidharan R; Gorospe M; Herman T; Ding WQ; Ramesh R; Munshi A
Oncotarget; 2016 Oct; 7(40):64820-64835. PubMed ID: 27588488
[TBL] [Abstract][Full Text] [Related]
19. HuR Suppresses Fas Expression and Correlates with Patient Outcome in Liver Cancer.
Zhu H; Berkova Z; Mathur R; Sehgal L; Khashab T; Tao RH; Ao X; Feng L; Sabichi AL; Blechacz B; Rashid A; Samaniego F
Mol Cancer Res; 2015 May; 13(5):809-18. PubMed ID: 25678597
[TBL] [Abstract][Full Text] [Related]
20. Chemo-biologic combinatorial drug delivery using folate receptor-targeted dendrimer nanoparticles for lung cancer treatment.
Amreddy N; Babu A; Panneerselvam J; Srivastava A; Muralidharan R; Chen A; Zhao YD; Munshi A; Ramesh R
Nanomedicine; 2018 Feb; 14(2):373-384. PubMed ID: 29155362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
